It also says: “ The Phase 2 randomized, placebo-controlled clinical trial includes approximately 120 hospitalized patients with moderate-to-severe COVID-19. Two intravenous treatment arms were enrolled—active and placebo, with ~60 patients per arm.”
The writer of this article assumes. The trials are ongoing.